Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001193125-23-251311
Filing Date
2023-10-05
Accepted
2023-10-05 12:23:50
Documents
2
Group Members
ALBERT CHADANIEL ESTESFHMLS X, L.L.C.FHMLS X, L.P.FHMLS XI, L.L.C.FHMLS XI, L.P.FHMLSP OVERAGE, L.L.C.FHMLSP OVERAGE, L.P.FHMLSP, L.L.C.FHMLSP, L.P.FRAZIER LIFE SCIENCES PUBLIC OVERAGE FUND, L.P.FRAZIER LIFE SCIENCES X, L.P.FRAZIER LIFE SCIENCES XI, L.P.J

Document Format Files

Seq Description Document Type Size
1 SC 13G/A d542507dsc13ga.htm SC 13G/A 275864
2 EX-99.A d542507dex99a.htm EX-99.A 31838
  Complete submission text file 0001193125-23-251311.txt   309848
Mailing Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451
Business Address 35 GATEHOUSE DRIVE BUILDING D, FLOOR 3 WALTHAM MA 02451 781-419-1400
Syndax Pharmaceuticals Inc (Subject) CIK: 0001395937 (see all company filings)

EIN.: 320162505 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-89449 | Film No.: 231310583
SIC: 2834 Pharmaceutical Preparations

Mailing Address TWO UNION SQUARE, 601 UNION ST. SUITE 3200 SEATTLE WA 98101
Business Address TWO UNION SQUARE, 601 UNION ST. SUITE 3200 SEATTLE WA 98101 650-325-5156
Frazier Life Sciences Public Fund, L.P. (Filed by) CIK: 0001863769 (see all company filings)

EIN.: 862999645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A